Literature DB >> 2447290

A C-terminal domain in the avian sarcoma-leukosis virus pol gene product is not essential for viral replication.

R A Katz1, A M Skalka.   

Abstract

The virion proteins encoded by the avian retroviral pol gene (reverse transcriptase and endonuclease) are formed by the proteolytic processing of a gag-pol fusion protein precursor. Recent studies have predicted that the avian sarcoma-leukosis virus pol precursor protein undergoes a previously undetected processing event resulting in the formation of common C termini for the endonuclease (pp32) and the beta subunit of reverse transcriptase (F. Alexander, J. Leis, D. A. Soltis, R. M. Crowl, W. Danho, M. S. Poonian, Y.-C. E. Pan, and A. M. Skalka, J. Virol. 61:534-542, 1987; D. Grandgenett, T. Quinn, P. J. Hippenmeyer, and S. Oroszlan, J. Biol. Chem. 260:8243-8249, 1985). This processing event removes 37 amino acids, thus defining a new pol domain. In this report, we present evidence that this C-terminal domain is translated as part of the gag-pol precursor but is not required for replication of the virus in tissue culture cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447290      PMCID: PMC250564     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Recombination between a defective retrovirus and homologous sequences in host DNA: reversion by patch repair.

Authors:  P Schwartzberg; J Colicelli; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

2.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.

Authors:  S Goff; P Traktman; D Baltimore
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

3.  Amino acid sequence analysis of reverse transcriptase subunits from avian myeloblastosis virus.

Authors:  T D Copeland; D P Grandgenett; S Oroszlan
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

4.  A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

5.  Nucleotide sequence of Rous sarcoma virus.

Authors:  D E Schwartz; R Tizard; W Gilbert
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

6.  Restriction endonuclease and nucleotide sequence analyses of molecularly cloned unintegrated avian tumor virus DNA: structure of large terminal repeats in circle junctions.

Authors:  R A Katz; C A Omer; J H Weis; S A Mitsialis; A J Faras; R V Guntaka
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

7.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose.

Authors:  J Kyhse-Andersen
Journal:  J Biochem Biophys Methods       Date:  1984-12

8.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

9.  Avian sarcoma and leukosis virus pol-endonuclease recognition of the tandem long terminal repeat junction: minimum site required for cleavage is also required for viral growth.

Authors:  D Cobrinik; R Katz; R Terry; A M Skalka; J Leis
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Newly generated avian erythroblastosis virus produces noninfectious particles lacking env-gene products.

Authors:  T Yamamoto; S Kawai; T Koyama; H Hihara; T Shimizu; K Toyoshima
Journal:  Virology       Date:  1983-08       Impact factor: 3.616

View more
  19 in total

1.  Asymmetric subunit organization of heterodimeric Rous sarcoma virus reverse transcriptase alphabeta: localization of the polymerase and RNase H active sites in the alpha subunit.

Authors:  S Werner; B M Wöhrl
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Defining nucleic acid-binding properties of avian retrovirus integrase by deletion analysis.

Authors:  S R Mumm; D P Grandgenett
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

3.  Phosphorylation of the avian retrovirus integration protein and proteolytic processing of its carboxyl terminus.

Authors:  R Horton; S R Mumm; D P Grandgenett
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

4.  Retroviral integrase domains: DNA binding and the recognition of LTR sequences.

Authors:  E Khan; J P Mack; R A Katz; J Kulkosky; A M Skalka
Journal:  Nucleic Acids Res       Date:  1991-02-25       Impact factor: 16.971

5.  Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells.

Authors:  L Stewart; V M Vogt
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Control of retroviral RNA splicing through maintenance of suboptimal processing signals.

Authors:  R A Katz; A M Skalka
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

7.  A C-terminal "Tail" Region in the Rous Sarcoma Virus Integrase Provides High Plasticity of Functional Integrase Oligomerization during Intasome Assembly.

Authors:  Krishan K Pandey; Sibes Bera; Ke Shi; Hideki Aihara; Duane P Grandgenett
Journal:  J Biol Chem       Date:  2017-02-08       Impact factor: 5.157

8.  cis-acting intron mutations that affect the efficiency of avian retroviral RNA splicing: implication for mechanisms of control.

Authors:  R A Katz; M Kotler; A M Skalka
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 9.  Piecing together the structure of retroviral integrase, an important target in AIDS therapy.

Authors:  Mariusz Jaskolski; Jerry N Alexandratos; Grzegorz Bujacz; Alexander Wlodawer
Journal:  FEBS J       Date:  2009-04-14       Impact factor: 5.542

10.  On the early emergence of reverse transcription: theoretical basis and experimental evidence.

Authors:  A Lazcano; V Valverde; G Hernández; P Gariglio; G E Fox; J Oró
Journal:  J Mol Evol       Date:  1992-12       Impact factor: 2.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.